USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SYNTRIX BIOSYSTEMS, INC.
Address:
215 CLAY ST NW, STE B-5
AUBURN, WA
Phone:
N/A
URL:
N/A
EIN:
911981291
DUNS:
114845659
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $6,731,789.00 15
SBIR Phase II $13,368,531.00 6

Award List:

Novel GSTP Inhibitors As Potential Oral Myelostimulants

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$250,077.00
Agency:
HHS
Principal Investigator:
John A. Zebala
Abstract:
DESCRIPTION (provided by applicant): Myelosuppression is a common complication of cancer treatment that limits the efficacy of conventional chemotherapy. It has been demonstrated that inhibiting glutathione S-transferase… More

SNAP-TO-IT PNA ARRAYS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$283,728.00
Agency:
HHS
Principal Investigator:
Abstract:
Microarrays offer the potential to profile genetic alterations in a highly multiplexed format, but have suffered the sub-optimal specificity of target capture. Array technologies which improve the specificity of target capture will be of commercial value by allowing the manufacture of arrays with… More

LIGHT-UP PNA ARRAYS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$296,151.00
Agency:
HHS
Principal Investigator:
Abstract:
Microarrays offer the potential to profile the molecular alterations in cancer in a highly multiplexed format, but have suffered from sub- optimal sensitivity, specificity and ease-of-use. Array technologies with improved performance characteristics will therefore be of commercial value in cancer… More

Instrumentation For High-Resolution Analysis of Cancer

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
John A. Zebala
Abstract:
DESCRIPTION (provided by applicant): The analysis of cancer within complex heterogeneous tissues represents special challenges posed by the presence of infiltrating non-neoplastic cells. We have developed biolithography, a novel and proprietary method (U.S. Pat. No. 6,159,681 to Syntrix, Inc.)… More

Artificial Antibody Mimetics

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
John A. Zebala
Abstract:
DESCRIPTION (provided by applicant): Among the many mechanisms by which cancer arises, it is now appreciated that inappropriate phosphorylation is a key pathway. Detection agents capable of binding discrete phosphoproteins with high specificity will be important tools for research, diagnostics,… More

Bronchopulmonary Dysplasia Drug Therapy

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$163,329.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Neutrophils are bloodborne inflammatory cells that exhibit potent oxidative and phagocytic activities. One important component of the neutrophils' role in the immune system is its ability to migrate rapidly towards sites of inflammation in a process known as… More

Meta-Molding Arrays

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
John A. Zebala
Abstract:
DESCRIPTION (provided by applicant): Protein chips offer the potential to profile the levels and kinetics of proteins in tissues of the digestive and endocrine systems in a highly multiplexed format. Despite this potential, the majority of protein chips are based on arrayed bio-molecules obtained… More

Instrumentation For High-Resolution Analysis of Cancer

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$2,266,035.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The analysis of cancer within complex heterogeneous tissues represents special challenges posed by the presence of infiltrating non-neoplastic cells. We have developed biolithography, a novel and proprietary method (U.S. Pat. No. 6,159,681 to Syntrix, Inc.)… More

Artificial Antibody Mimetics

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$2,176,018.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Among the many mechanisms by which cancer arises, it is now appreciated that inappropriate phosphorylation is a key pathway. Detection agents capable of binding discrete phosphoproteins with high specificity will be important tools for research, diagnostics,… More

Novel Oral Trojan-Horse Agents for Osteolytic Cancer

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$546,002.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The bisphosphonates have emerged as powerful new weapons in the therapeutic arsenal employed to treat bone metastases and cancer osteolysis. These metabolically stable pyrophosphate mimetics incorporate in bone and interact with osteoclasts and osteoblasts… More

Bronchopulmonary Dysplasia Drug Therapy

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$2,122,078.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Bronchopulmonary dysplasia (BPD) is a disease affecting infants who become oxygen dependent as a result of prolonged mechanical ventilation with supplemental oxygen early in life. Barotrauma and elevated levels of oxygen induce direct injury to the immature lung… More

Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$791,030.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Aminotrexate(tm) (AMT) is an antifolate in the same class as MIX that we have established is nearly 100% orally bioavailable in humans with a lower interpatient coefficient of variation than MTX, and is much more rapidly taken up by cells and tissues. With regard… More

Snap-To-It Probes

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$1,164,115.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Microarrays offer the potential to profile genetic alterations in a highly multiplexed format, but have suffered from sub-optimal specificity of target capture. Array technologies which improve the specificity of target capture will be of commercial value by… More

Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$587,148.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Atopic dermatitis (AD) is an itchy, inflammatory skin disease. It is one of the most common causes of human and canine disability. The incidence of human atopic dermatitis is steadily increasing. The mainstay of therapy for milder human disease is topical… More

PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$698,900.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The spatiotemporal modulation of gene expression using targeted light to activate antisense molecules promises to have an important impact in transparent model organisms, where irradiation can be specifically targeted visually to known anatomic landmarks.… More

The Treatment of Methotrexate Resistant Rheumatoid Arthritis With Aminopterin

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$518,627.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project is to develop aminopterin (AMT), an antifolate medication, as an improved treatment for patients with rheumatoid arthritis (RA) and other inflammatory diseases. This application focus es on RA which occurs in ~1% of the… More

99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$590,144.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) occurs in 2,100,000 people in the United States, and is associated with progressive joint destruction, functional disability and decreased life expectancy. Joint destruction does not occur with out synovial inflammation. The treatment of… More

Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$649,545.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with 18,526,000 prescriptions and 281,559,000 in retail sales in 2007, making it the 31st best selling generic drug. One of the advantages of tramadol over traditional opioids is its lower risk of opioid dependence,… More

Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$3,846,324.00
Agency:
HHS
Principal Investigator:
Dean Y. Maeda – 253-833-8009
Abstract:
DESCRIPTION (provided by applicant): SX-576 is a small molecule CXCR1/2 antagonist that potently blocks the migration of neutrophils to sites of injury and/or inflammation. SX-576 is being developed as a potential therapeutic for the treatment of pulmonaryinflammatory diseases, such as… More

Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$557,508.00
Agency:
HHS
Principal Investigator:
John A. Zebala – 253-833-8009
Abstract:
DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (Mtb) is a notorious pathogen whose increasing resistance to antibiotics and heightened lethality in combination with AIDS makes it a major health concern worldwide. The selection and spread of multiple drug resistant Mtb continued for… More

Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,793,961.00
Agency:
HHS
Principal Investigator:
Stuart J. Kahn – 253-833-8009
Abstract:
DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with over 25 million prescriptions and 565 million in retail sales in 2009, making it among the best selling generic drugs. One of the advantages of tramadol over traditionalopioids is its lower risk of opioid… More